The Hong Kong Private Equity group led a cross-office Goodwin team on advising Templewater on its acquisition of The Women’s Clinic Group Limited (“TWCG”), a leading Hong Kong-based provider of specialist women’s health and fertility services. The transaction further strengthens Templewater’s healthcare portfolio and reflects its commitment to building high-quality, patient-centric healthcare platforms that improve access to specialist medical services across Asia.
TWCG is one of Hong Kong’s largest and most established private women’s healthcare specialist groups. It operates a network of six clinics, three IVF laboratories, and one blood laboratory across Hong Kong and Singapore, providing a comprehensive range of fertility, obstetrics and gynaecology (“O&G”), and traditional Chinese medicine services.
Templewater is an Asia-based alternative asset manager headquartered in Hong Kong. Templewater provides investment solutions to global institutions, family offices, and high-net-worth inpiduals, with a focus on two core pan-Asia strategies: mid-market private equity buyouts and energy transition venture growth. Templewater’s mission is to provide financial and human capital, operational expertise, a corporate governance framework, and integrity to build leading businesses.
The cross office Goodwin team was led by Edwin Chan and included Ingram Cheung, Andrew Mon, Cecilia Chen, Eugena Tong, Gabriel Lee, Julia Lim, Dorothy Hou, and Monique Chan (Private Equity M&A); Steve Howard, Dora Cheung, and Christopher Ho (Debt Finance); Dominic Wong, Ian Goh, and Faye Wong (Private Investment Funds); Ai Tajima (Risk Management & Insurance); Dulcie Daly and Matthew Rees (Tax); Gabe Maldoff (Technology); David Chen and Longfei Fang (Life Sciences, Privacy & IP); and Bill Stern, Ce Li, and Nick Ognibene (ABC/AML).
For more information on the deal, please read the press release.